Brand Name

Nubeqa

Generic Name
Darolutamide
View Brand Information
FDA approval date: July 31, 2019
Form: Tablet

What is Nubeqa (Darolutamide)?

NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer . , metastatic hormone-sensitive prostate cancer in combination with docetaxel. NUBEQA is indicated for the treatment of adult patients with:, non-metastatic castration resistant prostate cancer , metastatic hormone-sensitive prostate cancer in combination with docetaxel.

Approved To Treat

Top Global Experts

Save this treatment for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms

Related Clinical Trials

An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)
An Open-label, Randomised, Phase-I, Multi-Centre Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men With Newly Diagnosed Prostate Cancer (ASCERTAIN)
Enrollment Status: Recruiting
Publish Date: December 16, 2025
Intervention Type: Other, Drug
Study Phase: Phase 1

Summary: A Study to Investigate the Biological Effects of Saruparib (AZD5305) Alone, Darolutamide Alone, and in Combination Given Prior to Radical Prostatectomy in Men with Newly Diagnosed Prostate Cancer (ASCERTAIN).

Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients
Post-marketing Surveillance Study for Approved Darolutamide Use in Korean Patients
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug

Summary: This is an observational study in which participants receive a treatment which is already available for doctors to prescribe for non-metastatic castration-resistant prostate cancer (nmCRPC) or metastatic hormone-sensitive prostate cancer (mHSPC). nmCRPC is a prostate cancer that has not yet spread to other parts of the body and does not respond to lowering testosterone in the body. mHSPC is a pros...

A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
A Phase 1b Study of JNJ-78278343, a T-cell Redirecting Agent Targeting Human Kallikrein 2 (KLK2), in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer
Enrollment Status: Recruiting
Publish Date: December 05, 2025
Intervention Type: Drug
Study Phase: Phase 1

Summary: The purpose of this study is to identify the recommended phase 2 regimen(s) RP2R(s) of JNJ-78278343 and combination agent in Part 1 (dose escalation) and to determine safety at the putative RP2R(s) of JNJ-78278343 with the combination agent in Part 2 (dose expansion).

View All Clinical Trials

Related Latest Advances

A rare case of isolated lung metastases in prostate cancer.
A rare case of isolated lung metastases in prostate cancer.
Journal: Hellenic journal of nuclear medicine
Published: November 17, 2025
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Darolutamide plus androgen-deprivation therapy in high-risk biochemical recurrence of prostate cancer (ARASTEP).
Journal: Future oncology (London, England)
Published: November 11, 2025
Unexpected Fatal Pneumocystis Jirovecii Pneumonia During Triplet Therapy for Hormone-Sensitive Prostate Cancer.
Unexpected Fatal Pneumocystis Jirovecii Pneumonia During Triplet Therapy for Hormone-Sensitive Prostate Cancer.
Journal: Respirology case reports
Published: October 31, 2025
View All Latest Advances

Brand Information

NUBEQA (darolutamide)
1DOSAGE FORMS AND STRENGTHS
Tablets (300 mg): white to off-white oval film-coated tablets marked with "300" on one side and "Bayer" on the other.
2CONTRAINDICATIONS
None.
3OVERDOSAGE
There is no known specific antidote for darolutamide overdose. The highest dose of NUBEQA studied clinically was 900 mg twice daily, equivalent to a total daily dose of 1800 mg. No dose limiting toxicities were observed with this dose.
Considering the saturable absorption and the absence of evidence for acute toxicity, an intake of a higher than recommended dose of darolutamide is not expected to lead to systemic toxicity in patients with intact hepatic and renal function
In the event of intake of a higher than recommended dose in patients with severe renal impairment or moderate hepatic impairment, if there is suspicion of toxicity, interrupt NUBEQA treatment and undertake general supportive measures until clinical toxicity has been diminished or resolved. If there is no suspicion of toxicity, NUBEQA treatment can be continued with the next dose as scheduled.
4DESCRIPTION
NUBEQA is an androgen receptor inhibitor. The chemical name is N-{(2S)-1-[3-(3-chloro-4-cyanophenyl)-1H-pyrazol-1-yl]propan-2-yl}-5-(1-hydroxyethyl)-1H-pyrazole-3-carboxamide.
Chemical Structure
The molecular weight is 398.85 and the molecular formula is C
Darolutamide is an optically active with a specific rotation value [α]
NUBEQA (darolutamide) is supplied as film-coated tablets containing 300 mg of darolutamide for oral use. The inactive ingredients of the tablet are: calcium hydrogen phosphate, croscarmellose sodium, lactose monohydrate, magnesium stearate, povidone K 30, hypromellose 15 cP, macrogol 3350, and titanium dioxide.
5PATIENT COUNSELING INFORMATION
Advise the patient to read the FDA-approved patient labeling (Patient Information)
6PACKAGE/LABEL PRINCIPAL DISPLAY PANEL
50419-395-01
Rx Only
NUBEQA
(darolutamide) tablets
300 mg
120 film-coated tablets
NUBEQA 300 mg label